NCT06375486View on ClinicalTrials.gov

Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）.

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 14, 2024

Primary Completion Date

March 14, 2025

Study Completion Date

June 15, 2026

Conditions
Hepatocellular Carcinoma Non-resectableHepatocellular Carcinoma
Interventions
DRUG

Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）

All enrolled subjects will receive Ivonescimab（AK112，a PD-1/VEGF bispecific antibody，20mg/kg Q3W) in combination with HAIC (utilizing the FOLFOX chemotherapy regimen)

Trial Locations (1)

300308

RECRUITING

Tianjin Cancer Hospital Airport Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER